A highly constrained pseudo-tetrapeptide (OC252-324) further defines a new allosteric binding site located near the center of fructose-1,6-bisphosphatase. In a crystal structure, pairs of inhibitory molecules bind to opposite faces of the enzyme tetramer. Each ligand molecule is in contact with three of four subunits of the tetramer, hydrogen bonding with the side chain of Asp 187 and the backbone carbonyl of residue 71, and electrostatically interacting with the backbone carbonyl of residue 51. The ligated complex adopts a quaternary structure between the canonical R-and T-states of fructose-1,6-bisphosphatase, and yet a dynamic loop essential for catalysis (residues 52؊72) is in a conformation identical to that of the T-state enzyme. Inhibition by the pseudo-tetrapeptide is cooperative (Hill coefficient of 2), synergistic with both AMP and fructose 2,6-bisphosphate, noncompetitive with respect to Mg
Fructose-1,6-bisphosphatase (D-fructose-1,6-bisphosphate 1-phosphohydrolase, EC 3.1.3.11; FBPase) 1 catalyzes a tightly regulated step of gluconeogenesis, the hydrolysis of fructose 1,6-bisphosphate (F16P 2 ) to fructose 6-phosphate (F6P) and P i (1, 2) . AMP and F26P 2 (binding to allosteric and active sites, respectively) inhibit FBPase, while simultaneously activating its counterpart in glycolysis, fructose-6-phosphate 1-kinase (3, 4) . Biosynthesis and degradation of F26P 2 is subject to hormonal control principally by glucagon and insulin (4, 5) . F26P 2 enhances the binding of AMP to FBPase by up to an order of magnitude (6) . Hence, although intracellular concentrations of AMP remain relatively constant, AMP becomes a more potent inhibitor of FBPase as concentrations of F26P 2 increase. AMP binds 28 Å away from the nearest active site and perhaps not surprisingly inhibits catalysis noncompetitively with respect to F16P 2 . Yet AMP is a competitive inhibitor of catalysis with respect to essential divalent cations (Mg 2ϩ , Mn 2ϩ , or Zn 2ϩ ), all of which are in proximity to (and probably coordinate with) the 1-phosphoryl group of F16P 2 (7Ϫ10).
FBPase is a homotetramer (subunit M r of 37,000 (11) ) and exists in at least two distinct quaternary conformations called R and T (12Ϫ14). AMP induces the transition from the active R-state to the inactive (or less active) T-state. Substrates or products in combination with metal cations stabilize the Rstate conformation. A proposed mechanism for allosteric regulation of catalysis involves three conformational states of loop 52Ϫ72 called engaged, disengaged, and disordered (15) . AMP alone or with F26P 2 stabilizes a disengaged loop (16, 17) , whereas metals with products stabilize an engaged loop (10, 17Ϫ19) . In active forms of the enzyme, loop 52Ϫ72 probably cycles between its engaged and disordered conformations (15, 18) . Fluorescence from a tryptophan reporter group at position 57 is consistent with the conformational states for loop 52Ϫ72, observed in crystal structures (20, 21) . Presumably, the engaged, disengaged, and disordered conformations of loop 52Ϫ72 are possible in both the R-and T-states of FBPase, but only the engaged and disordered conformers of the R-state, and the disengaged conformer of the T-state, have been reported in crystalline complexes (17, 18, 22, 23) .
A recent report (24) in the literature identifies a new inhibitor site on FBPase, distinct from the active and the AMPbinding sites. The new family of anilinoquinazoline inhibitors was discovered by a search for potential drugs in the treatment of non-insulin-dependent diabetes. Although the site of binding on FBPase is clear, the kinetic mechanism of inhibition for this new class of inhibitor was not reported. Independent of the efforts above, a screen for new inhibitors of FBPase resulted in the discovery of a chemically distinct molecule (OC252-324, hereafter OC252, Fig. 1 ) that targets the same binding site on FBPase. Inhibition of FBPase by OC252 is cooperative (Hill coefficient of 2), synergistic with AMP and F26P 2 , noncompetitive with respect to Mg 2ϩ , but uncompetitive with respect to F16P 2 . OC252 greatly decreases the concentration at which substrate inhibition dominates the kinetics of FBPase. The crystal structure reveals a pair of OC252 molecules bound to each face of an FBPase tetramer. The quaternary conformation of the tetramer differs from the canonical R-and T-states, observed in the absence and presence of AMP, respectively, yet the loop (residues 52Ϫ72) is in its disengaged conformation. A strong hydrogen bond between OC252 and the side chain of a conserved aspartate residue of undetermined functional significance suggests the possibility of a binding site recognized by an unknown natural effector.
EXPERIMENTAL PROCEDURES
Materials-F16P 2 , F26P 2 , NADP ϩ , and AMP were purchased from Sigma. Glucose-6-phosphate dehydrogenase and phosphoglucose isomerase came from Roche Applied Science. Other chemicals were of reagent grade or the equivalent. QSW-HR high pressure liquid chromatography resin came from Toso-Hass Bioseparations. FBPase-deficient Escherichia coli strain DF 657 came from the Genetic Stock Center at Yale University. Plasmids used in the expression of wild-type FBPase came from a previous investigation (20) . The inhibitor OC252 was provided by Ontogen Corp. (Carlsbad, CA).
Expression and Purification of Wild-type FBPase-Separate preparations of enzyme were used for the structural and kinetics investigations. Recombinant FBPase was expressed in a strain of E. coli deficient in endogenous FBPase and then purified to homogeneity. Cell-free extracts of the wild-type FBPases were subjected to heat treatment (65°C for 5 min), followed by centrifugation. For enzyme used in kinetics investigations, the supernatant solution was loaded onto a Cibacron Blue-Sepharose column, previously equilibrated with 20 mM Tris-HCl, pH 7.5. FBPases were eluted from that column with 1 mM AMP and 20 mM Tris-HCl, pH 7.5. The eluent from the first column was loaded directly onto a DEAE-Sepharose column and then eluted with a NaCl gradient (0 -0.3 M). The purified enzyme was dialyzed extensively against 20 mM Tris-HCl, pH 7.5. For crystallization experiments, after volume reduction by pressure concentration through an Amicon PM-30 membrane, the supernatant solution from centrifugation was passed through a CM-Sepharose column using a NaCl gradient (20Ϫ400 mM) in 10 mM Tris malonate, pH 6.0, and then dialyzed against KP i (20 mM, pH 7.0). Purity and protein concentrations of FBPase preparations were confirmed by SDS-PAGE (25) and the Bradford assay (26), respectively.
Kinetic Experiments-Assays for the determination of specific activity, k cat , and activity ratios at pH 7.5 and 9.5 employed the coupling enzymes, phosphoglucose isomerase and glucose-6-phosphate dehydrogenase (1). The reduction of NADP ϩ to NADPH was monitored by absorbance spectroscopy at 340 nm. All other assays used the same coupling enzymes, but monitored NADPH production by its fluorescence emission at 470 nm, using an excitation wavelength of 340 nm. Kinetic assays were performed at room temperature (22°C). Data fitting and analysis used the program DYNAFIT (27) .
Crystallization of the Product Complex-Crystals of FBPase grew by the method of hanging drops. Equal parts of a protein solution (FBPase (10 mg/ml), KP i , pH 7.4 (10 mM), MgCl 2 (5 mM), F6P (5 mM), and OC252 (2 mM)) and a precipitant solution (Tris malonate, pH 7.4 (2.5 mM), polyethylene glycol 3350 (6% w/v)) were combined in a droplet of 4 l total volume. Wells contained 500 l of the precipitant solution. Crystals of dimensions 0.4 ϫ 0.4 ϫ 0.3 mm grew in approximately 3 days at 20°C. OC252 is relatively insoluble in aqueous solutions. Approximately 10 mg of pure inhibitor was dissolved initially in acetone, and appropriately measured aliquots were distributed to empty vials. The acetone was removed by evaporation, and the protein solution above was added. The inhibitor dissolved after a brief time interval to provide the clear protein solution used in the crystallization experiments.
Data Collection-Data were collected at Iowa State University on a rotating anode/Siemens area detector at 120 K, using CuK ␣ radiation passed through a graphite monochromator. Data were reduced by XEN-GEN (28) .
Structure Determination, Model Building, and Refinement-Crystals grown for the present study are isomorphous to the AMP-Zn 2ϩ -product complex (17) . Phase angles, used in the generation of initial electron density maps, were based on model 1EYJ of the Protein Data Bank, from which water molecules, metal cations, small molecule ligands, and residues 52Ϫ72 had been omitted. Residues 52Ϫ72 were built into the electron density of omit maps, with reference to the C␣ coordinates of loop 52Ϫ72 from the AMP complex (17), using the program XTALVIEW FIG. 1. Covalent structure of OC252. Atoms C-8, C-10, C-12, and C-14 correspond to C␣ atoms of residues labeled 1Ϫ4. Atoms C-8, C-10, and C-12 adopt the L-configuration of a common amino acid. Residues 1 and 4 have tyrosyl side chains; residue 2 has a phenylalanine side chain bridged by a methylene group to its amide nitrogen atom (N-1), and residue 3 has an n-propyl side chain. In its crystalline complex, a close contact between atoms N-3 and O-3 infers a strong intramolecular hydrogen bond. The electronic resonance state of the bond between atoms N-2 and C-11 is speculative but would account for the close contact between backbone carbonyl 51 (from FBPase) and atom N-2 through enhanced electrostatic interactions.
(29) and a Silicon Graphics work station. A molecule of P i and of F6P and two magnesium cations were added to omit electron density of the active site. Strong electron density remained, however, near the center of the tetramer, which easily accommodated a molecule of OC252. The resulting model underwent refinement, using CNS (30) with force constants and parameters of stereochemistry from Engh and Huber (31) . A cycle of refinement consisted of slow cooling from 2500 to 300 K in steps of 25 K, followed by 120 cycles of conjugate gradient minimization, and concluded by the refinement of individual thermal parameters. Thermal parameter refinement employed restraints of 1.5 Å 2 on nearest neighbor and next-to-nearest neighbor main chain atoms, 2.0 Å 2 on nearest neighbor side chain atoms, and 2.5 Å 2 on next-to-nearest neighbor side chain atoms.
In subsequent cycles of refinement, water molecules were fit to difference electron density of 2.5 or better and were added until no significant decrease was evident in the R free value. Included in the final model were water molecules that make suitable donor-acceptor distances to each other and the protein and have thermal parameters under 60 Å 2 .
RESULTS

Expression and Purification of Wild-type
FBPase-Expression and isolation procedures described above provide FBPase in at least 95% purity, as judged by SDS-PAGE (data not shown). The k cat value (22 Ϯ 1 s Ϫ1 ) and the ratio of specific activities at pH 7.5 to 9.5 (3.3) indicate high purity and little or no proteolysis of the purified enzyme, consistent with the results from electrophoresis.
Kinetics Experiments-By using fixed concentrations of 
where n is the Hill coefficient, V m the initial velocity in the absence of inhibitor, V o the initial velocity at a specific inhibitor concentration, I the concentration of OC252, and I 0.5 the concentration of OC252 that causes 50% inhibition. Kinetics data were taken over broad concentration ranges of Mg 2ϩ (0.2Ϫ5 mM), F16P 2 (1Ϫ20 M), and OC252 (0Ϫ20 M) in order to determine the kinetic mechanism of inhibition. (Fig. 3) . As is evident from Fig. 3A , substrate inhibition increases significantly with rising inhibitor concentration. Data from Fig. 3A were fit to nine different Fructose-1,6-bisphosphatasekinetic models using the program DYNAFIT (27) , combining mechanisms of competitive, noncompetitive, and uncompetitive inhibition by OC252, with and without pathways for inhibitor-induced substrate inhibition or partial inhibitor-induced substrate inhibition (Table I) Table I represents the data at saturating Mg 2ϩ with the fewest parameters. Scheme I then represents the kinetic mechanism of inhibition at all concentrations of the relevant ligands.
From Scheme I we derived the following relationship (Equation 2) assuming rapid-equilibrium kinetics under initial velocity conditions,
where A, B, and I are concentrations of free Mg 2ϩ , F16P 2 , and OC252, respectively; V m is the maximal velocity, and 
which is used in the determination of V m , K b , K ii , and K iis from data in Fig. 3A . Under these conditions, [F16P 2 ]Ͼ ϾK b , Equation 2 simplifies to Equation 4,
which is used in the determination of V m , K a , and K i from data in Fig. 3B (17) . Two subunits of FBPase are in the asymmetric unit of this crystal form. C␣ coordinates of the independent subunits superimposed with a root mean square deviation of 0.38 Å, using a subset of residues (33Ϫ49, 75Ϫ265, and 272Ϫ330), which do not exhibit significant tertiary conformational differences between the T-and R-state subunits of FBPase (10). Regions of Fructose-1,6-bisphosphataseweak or absent electron density include residues 1Ϫ8 and 63Ϫ70. The model begins at residue 9 and continues to the last residue of the sequence, but segment 63Ϫ70 is unreliable, as evidenced by high thermal parameters. Thermal parameters vary from 5 to 57 Å 2 . As determined by PROCHECK (32), the model has stereochemistry generally comparable with that of structures derived from data of nominal resolution 2.0 Å. Statistics for data collection and refinement are in Table III , and an overview of the complex appears in Fig. 4 .
Although the two subunits of the OC252 complex are similar, the ligation of each active site by metals differs. In the subunit labeled chain B, strong electron density is at metal site 1. The thermal parameter of Mg 2ϩ at full occupancy here refines to a value of 10 Å 2 , which is significantly less than the average value (20 Å 2 ) for atoms of the protein ligated to that metal. Hence Mg 2ϩ and a heavier metal (Zn 2ϩ , on the basis of prior experience (19)) probably co-occupy site 1 in chain B. Site 2 of chain B has diffuse electron density that may represent disordered water molecules or the combination of water molecules and Mg 2ϩ at low occupancy; Mg 2ϩ at full occupancy refined at metal site 2 with a thermal parameter of 32 Å 2 . In the subunit labeled chain A, Mg 2ϩ refines with thermal parameters of 18 and 29 Å 2 at sites 1 and 2, respectively. Metal site 2 in chain A may be occupied partially by Mg 2ϩ . The conformations of side chains near metal site 2 also differ in each of the symmetry unique subunits of the crystal. In addition, molecules of P i are at partial occupancy at each active site, but molecules of F6P are at full occupancy.
OC252 is arguably a highly constrained pseudo-tetrapeptide (Fig. 1) ; the first and fourth "residues" have tyrosyl side chains, a methylene group in residue 2 covalently bridges the phenylalanyl side chain to its amide nitrogen, and an n-propyl group is the side chain of residue 3. The N-2 atom of OC252 corresponds to the backbone nitrogen atom of the first and third residues, and the terminal carboxyl group is absent. Atoms C-8, C-10, and C-12 have the L-configuration of a common amino Fructose-1,6-bisphosphataseacid. In their FBPase complex, two molecules of OC252 are in mutual contact, related to each other by the molecular 2-fold axis that projects through the face of the FBPase tetramer. Most of the contacts between inhibitor and protein are apolar; however, the phenol oxygen atoms of residues 1 and 4 of OC252 hydrogen-bond with backbone carbonyl 71 and the side chain of Asp 187 , respectively. Furthermore, the C-O bond axis of backbone carbonyl 51 is normal to the plane defined by atoms C-8, N-2, C-11, and C-12 of OC252, with its oxygen atom 3.2 Å from atom N-2. The latter suggests an electronic resonance state of the bound OC252 molecule that stabilizes this close contact (Fig. 1) .
Although the OC252 and AMP crystalline complexes are isomorphous, the two FBPase tetramers adopt different quaternary conformations. Superpositions of C1ϪC2 subunit pairs from the OC252, T-state, and R-state complexes give comparable root mean squared deviations (Table IV) . (See Fig. 4 for the convention adopted in the labeling of subunits.) On the other hand, superpositions of tetramers give significantly larger deviations, suggesting different quaternary structures. Indeed, the C3ϪC4 subunit pair in the OC252 complex rotates ϳ14°r elative to the C1ϪC2 subunit pair, falling some 3°short of the canonical T-state (Fig. 5) . Hereafter, we refer to the quaternary state of FBPase induced by OC252 as the I-state.
The I-state must be due to the specific effects of the OC252 inhibitor. First, the conditions of crystallization for the T-, R-, and I-states of FBPase differ only by the presence or absence of allosteric effectors. The T-state crystallizes in the presence of AMP (17) , the I-state in the presence of OC252, and the R-state in the absence of allosteric effectors (10, 17) . Hence, ligation of FBPase by OC252 favors neither the T-nor R-state. OC252, however, stabilizes the disengaged conformation of loop 52Ϫ72, which prior to this work has been seen only in AMP-ligated complexes. Moreover, rotation of the side chain of His 55 about its C␣ϪC␤ bond eliminates the only unfavorable contact between OC252 and the superimposed T-state. Hence, OC252 could bind to T-state FBPase in an AMPϪOC252 complex. On the other hand, residues 51Ϫ56 of the engaged loop (a conformation observed only in the R-state) and the side chain of the poorly ordered Phe 6 partially fill the OC252 binding pocket in the R-state. OC252 may still bind to the R-state enzyme, but at the very least loop 52Ϫ72 cannot be in its engaged conformation.
Although loop 52Ϫ72 represents the largest conformational difference at the tertiary level between subunits in the T-and R-states of FBPase, other significant changes occur in the vicinity of the AMP pocket. Helices H1 and H2 are ϳ2 Å closer to each other in the T-state than in the R-state, a difference attributed to the binding of AMP (14) . Comparison of I-state and T-state subunits, however, presents a more complex scenario. Relative to the T-state, the binding site for the base of AMP is hindered sterically in the I-state. The interaction of backbone amide 17 and Thr 31 with the 6-amino group of AMP would force the adenine base into an unfavorable contact (ϳ2.5 Å) with the C␤ atom of Glu 20 (Fig. 6) . Evidently, a conformational change in the last two turns of helix H1 relaxes this unfavorable contact but in so doing perturbs Glu 19 and Arg 22 . The side chains of Glu 19 and Arg 22 are in contact with residues 26Ϫ28 of a neighboring subunit (C1ϪC4/C2ϪC3 interface). Residues 26Ϫ28 in turn hydrogen-bond with the 5Ј-phosphoryl group of AMP. Evidently, the collapse of helices H1 and H2 onto the AMP pocket then is complete in the I-state. Further progress toward the T-state then requires hydrogen bonds of the 6-amino group of AMP to force conformational changes at the C1ϪC4/C2ϪC3 interface.
DISCUSSION
OC252 and anilinoquinazolines (24) recognize a common site on FBPase, but the binding modes of these inhibitors differ substantially. Each inhibitor-type binds as a pair, but bound anilinoquinazoline and OC252 molecules have orthogonal orientations; two aniliquinazoline molecules overlap distinct moieties of a single OC252 molecule (Fig. 7) . The quinazoline moiety of the anilinoquinazoline overlaps residues 1 and 2 of OC252, whereas the phenylthiazole moiety overlaps residue 3 of the other OC252 molecule. No part of the anilinoquinazoline molecule corresponds to residue 4 of OC252, the side chain of which hydrogen-bonds Asp 187 . In fact, the phenylthiazole moiety through stacking interactions positions the side chain of His 55 over the pocket occupied by the tyrosyl side chain of OC252 residue 4. The anilinoquinazoline is roughly crescentshaped; the ends of the crescent contact the surface of the FBPase tetramer with the curve of the crescent projecting outward. Residues 3 (n-propyl side chain) and 4 (tyrosyl side chain) of OC252, on the other hand, penetrate the interior of the tetramer. Hence, the number of contacts between OC252 and FBPase greatly exceeds that of the anilinoquinazoline. Each OC252 molecule interacts with residues from three of four subunits of FBPase, whereas each anilinoquinazoline molecule interacts with residues from a pair of subunits (Fig. 7) . Curiously, despite all the differences above, both inhibitor types foster stabilizing interactions with backbone carbonyl 51 of FBPase. For the anilinoquinazoline, the hydroxyl group of the phenylthiazole moiety hydrogen-bonds directly with backbone carbonyl 51, whereas atom N-2 of the OC252 molecule is in a possible electrostatic contact with the oxygen atom of the backbone carbonyl 51.
Inhibitors of wild-type FBPases are either competitive (such as F26P 2 ) or noncompetitive (such as AMP) with respect to F16P 2 . Uncompetitive inhibition of FBPase by OC252 with respect to the substrate is unusual but not unprecedented. The mutation of Arg 49 to cysteine changes the kinetic mechanism of AMP inhibition with respect to F16P 2 from noncompetitive to uncompetitive, but retains the competitive mechanism of AMP inhibition with respect to Mg 2ϩ (33 pates in several hydrogen-bonded interactions in the T-state of FBPase, and has low thermal parameters (20Ϫ25 Å 2 ), but is less ordered in the R-state, having thermal parameters of 40Ϫ45 Å 2 (17) . (Fig. 3B) . Binding synergism between OC252 and F16P 2 would occur if each ligand were to bind at distinct sites and stabilize a common conformational state of FBPase. Hence, the I-state observed in the OC252 complex may be similar to the quaternary state of FBPase in the presence of inhibitory concentrations of substrate. Ligation of FBPase by OC252 excludes the engaged conformation of loop 52Ϫ72, which is presumably required for catalysis. The I-state itself may disfavor the engaged conformation of loop 52Ϫ72, thereby accounting for the phenomenon of substrate inhibition of FBPase at concentrations of F16P 2 in excess of 30 M.
The I-state may also be the basis for synergistic inhibition of FBPase by OC252 and F26P 2 . Elevated levels of F26P 2 (200 M) cause a transition from the loop-engaged R-state to a conformation similar but not identical to the T-state, as measured by fluorescence from a Trp 57 reporter group (20) . Perhaps high concentrations of F26P 2 stabilize the I-state, and indeed the tetramer does adopt the I-state in a preliminary crystal structure of an F26P 2 -FBPase complex.
2 As OC252 and F26P 2 stabilize the same quaternary conformation by interactions at topologically distinct sites, they must exhibit functional synergism in rapid equilibrium kinetics.
An explanation of the synergism between AMP and OC252 is only slightly more complex. OC252 clearly excludes the engaged conformer of loop 52Ϫ72 and evidently stabilizes the disengaged loop present in the AMP complex of FBPase. Moreover, the I-state probably lies on or near the free energy pathway connecting the R-and T-states. So by stabilizing the Istate, OC252 does much of the work that AMP normally accomplishes in driving the R-to T-state transition.
But is the I-state of FBPase an appropriate target for the development of new drugs? Estimates of the free concentrations of Fructose-1,6-bisphosphatasepocket of FBPase could be an effective target, even if prevailing conditions in vivo do not favor the I-state.
Assays used to screen for potent inhibition of FBPase have employed concentrations of F16P 2 as high as 500 M (24). These conditions exclude inhibitors that compete with F16P 2 and bias the screen in favor of ligands that inhibit FBPase only in the presence of bound F16P 2 . Although this strategy has led to the discovery of molecules that do not bind to the active site, it has the disadvantage of selecting ligands that require high concentrations of F16P 2 for potent inhibition. For instance, I 0.5 is low (ϳ6 M) for OC252 in the presence of 100 M F16P 2 but rises to 70 M at a concentration of 2 M F16P 2 . Hence, an initial screen using high concentrations of F16P 2 may identify new leads that target the central allosteric site of FBPase, but further kinetic analysis at low concentrations of F16P 2 may be more appropriate in optimizing the lead compound as a potent inhibitor in vivo.
The above also assumes that no consequence beyond inhibition will result from the ligation of the central allosteric pocket of FBPase. Such an assumption, however, may be unwarranted. Available sequences of FBPase reveal Asp 187 as an invariant residue. The mutation of Asp 187 to alanine has only a modest effect on the functional properties of FBPase (36) . Its mutation to phenylalanine has no greater effect on FBPase function than that due to the alanine mutation. 3 What selective pressure then retains aspartate at position 187 and is it just coincidence that OC252 hydrogen-bonds to this side chain? The conservation of Asp 187 suggests a role in the recognition of a natural effector. Several reports (37Ϫ40) are in the literature, for instance, regarding interactions between FBPase and aldolase. The C-terminal residues of aldolase are putatively essential to these interactions, and the consensus sequences for both type A and B isozymes of aldolase end in tyrosine, which matches residue 4 of OC252. Hence, a potential drug may have to compete with a natural effector for the central allosteric pocket, or possibly FBPase itself may act as an effector in some other physiological process. Further clarification of these issues may be critical to the success of efforts to develop drugs that effectively target FBPase.
